Since AID does not act on all transcribed regions, transcription at AID targets may be special in some way. Indeed, AID off-targets in non-Ig loci tend to be convergently transcribed. 4, 5 How convergent transcription attracts AID to off-targets, and whether or not it is involved in on-target activity at Ig loci has not been fully elucidated. The study by Chen and colleagues, which is reported recently in Cell Research, 6 shed some light on this question. Chen and colleagues investigated the AID targeting mechanism by searching for factors that interact with AID and guide AID to genomic targets. The approach is a well-trodden path and, over the years, has yielded a bewilderingly large collection of AIDinteracting proteins. However, the role of many of these putative co-factors remains to be rigorously validated by functional assays in vivo. In this crucial respect, the AID-interacting protein identified by Chen and colleagues, ROD1/PTBP3, 7 stands out from the crowd. To test the function of ROD1, the authors knocked out its gene in mice. Remarkably, ROD1 deficiency led to severe reductions in both CSR and SHM. The phenotype is not an indirect consequence of defects in related processes. In this regard, ROD1-knockout mice contain normal B cell populations in different developmental stages, including germinal center B cells, where CSR and SHM take place. In response to B cell activation signals in vitro, the ROD1-deficient B cells proliferate, upregulate AID expression, and transcribe various switch regions at comparable levels as wild-type B cells. In light of the direct interaction between AID and ROD1, the most plausible interpretation of the phenotype is that loss of ROD1 directly impairs AID function. ROD1 protein is a family member of RNA-binding proteins that exhibit high affinity for polypyrimidine tracts. 8 The protein consists of a tandem array of four RRM-type RNA binding domains. Based on a genome-wide survey, ROD1 preferentially associates with transcripts that originate from bi-directionally transcribed loci. In line with the association between AID and ROD1, AID exhibits similar RNA binding profiles to ROD1, and the interaction is ROD1-dependent. Based on these observations, the authors proposed that ROD1 binds nascent transcripts at bi-directionally transcribed loci and recruits AID to these targets.
The model raises several questions. First, like other polypyrimidine tract-binding proteins, ROD1 preferentially interacts with pyrimidine-rich motifs in RNA. Paradoxically, transcription of one of the most prominent AID targets, switch region, yields predominantly G-rich transcripts. Transcripts from Ig variable regions are not notable for high pyrimidine content either. How could ROD1 recognize transcripts from these bona fide AID targets? Second, to guide AID to DNA, ROD1 must bind to nascent transcript that is still attached to template. Interaction with free transcript is counterproductive, as ROD1 would divert AID away from its genomic target. How could ROD1 differentiate a nascent transcript from the swarm of free transcripts with the same sequence? Bi-directional transcription is unlikely to be a specific mark for ROD1 or AID targets either, as divergent transcription near promoters is a common trait of many loci. Instead, convergent transcription provides a more definitive correlation with AID non-Ig off-targets, although the association remains to be established for the two main AID targets: switch regions and Ig variable regions. Thus, additional work is needed to determine whether and how ROD1 targets convergently transcribed regions and, more importantly, whether the mechanism applies to the physiological AID targets at the Ig loci. 
